ProteinScience.com - France,Spain,Portugal

France, Spain and Portugal

Paris

NEUROLAB your Research Partner is also dedicated to your discovery, preclinical, clinical and drug development programs. Through its worldwide network of research expertises it will help you progress faster in your programs in the fields of Neurosciences and Oncology. Functional Proteomics Programs to perform biomarkers discovery (profiling, identification, characterization and validation).

Hybrigenics is a leader in Functional proteomics, the study of the role and functions of proteins in cellular pathways. Hybrigenics thus addresses the major current need of the pharmaceutical industry, validation of high quality therapeutic targets allowing an improved success rate of novel compound development. The Company has developed integrated biological experiment-based and in silico-based technology platforms that allow identification, selection, prioritization and validation of drug targets. Hybrigenics' strategy is to use these platforms on an industrial scale to discover and validate novel targets for biopharmaceutical companies and to build a pipeline of proprietary biomarkers, small molecules and antibody drug products.

Roubaix

Bio-Xtal is centred around three main poles of activity: SOPNET™ (Soluble Protein Network). The aim of SoPNet is to upgrade the value of new or old structures resolved by Bio-Xtal's European academic laboratory partners. Industrials interested in these structures can request services from Bio-Xtal (complex studies, protein production) for the subjects proposed in the catalogue. A percentage of the turnover generated by the upgrading of these "academic" structures is redistributed to our partner laboratories to finance the resolution of new structures. MEPNET™ (Membrane Protein Network): Bio-Xtal has engineered the creation of a unique, global research consortium to study 100 G-Protein Coupled Receptors (GPCRs). The objective of this programme is to overcome the problems linked to GPCR production, purification, extraction, solubilisation, stabilisation and crystallisation. This consortium currently boasts the participation of over 40 major pharmaceutical and biotech companies, as well as 4 European academic laboratories. The MePNet programme was launched in September 2001. For more information, you could visit the web side of the program www.mepnet.org. Providing Structural Services: One of the company's aims is to provide a high quality of technology to health care specialists in the field of structural biology through our high throughput crystallography platform. We are able to undertake all the different stages of molecular biology and biochemistry, up to structure resolution. These services focus on new structure resolution and protein-inhibitor complex studies.